Clinical Trial Detail

NCT ID NCT02750215
Title A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

lung non-small cell carcinoma

Therapies

Capmatinib

Age Groups: adult senior

No variant requirements are available.